X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs GLENMARK PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS GLENMARK PHARMA IPCA LABS/
GLENMARK PHARMA
 
P/E (TTM) x 45.0 12.2 369.1% View Chart
P/BV x 3.5 3.2 107.1% View Chart
Dividend Yield % 0.1 0.4 39.7%  

Financials

 IPCA LABS   GLENMARK PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
GLENMARK PHARMA
Mar-17
IPCA LABS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs643993 64.8%   
Low Rs503729 68.9%   
Sales per share (Unadj.) Rs254.4325.5 78.2%  
Earnings per share (Unadj.) Rs16.139.3 40.9%  
Cash flow per share (Unadj.) Rs29.848.7 61.2%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.20.2 75.2%  
Book value per share (Unadj.) Rs194.6159.2 122.2%  
Shares outstanding (eoy) m126.20282.17 44.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.32.6 85.1%   
Avg P/E ratio x35.721.9 162.7%  
P/CF ratio (eoy) x19.217.7 108.7%  
Price / Book Value ratio x2.95.4 54.4%  
Dividend payout %6.25.1 122.3%   
Avg Mkt Cap Rs m72,300242,991 29.8%   
No. of employees `00013.313.0 102.6%   
Total wages/salary Rs m6,96016,408 42.4%   
Avg. sales/employee Rs Th2,413.57,083.9 34.1%   
Avg. wages/employee Rs Th523.21,265.4 41.3%   
Avg. net profit/employee Rs Th152.4855.1 17.8%   
INCOME DATA
Net Sales Rs m32,10691,857 35.0%  
Other income Rs m226374 60.4%   
Total revenues Rs m32,33292,230 35.1%   
Gross profit Rs m4,44820,367 21.8%  
Depreciation Rs m1,7302,644 65.4%   
Interest Rs m2412,373 10.1%   
Profit before tax Rs m2,70315,724 17.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m6753,827 17.6%   
Profit after tax Rs m2,02811,088 18.3%  
Gross profit margin %13.922.2 62.5%  
Effective tax rate %25.024.3 102.6%   
Net profit margin %6.312.1 52.3%  
BALANCE SHEET DATA
Current assets Rs m17,34068,746 25.2%   
Current liabilities Rs m9,55927,027 35.4%   
Net working cap to sales %24.245.4 53.4%  
Current ratio x1.82.5 71.3%  
Inventory Days Days10085 118.0%  
Debtors Days Days5796 59.5%  
Net fixed assets Rs m20,77924,132 86.1%   
Share capital Rs m252282 89.4%   
"Free" reserves Rs m24,49944,643 54.9%   
Net worth Rs m24,55344,925 54.7%   
Long term debt Rs m3,51745,363 7.8%   
Total assets Rs m39,595117,639 33.7%  
Interest coverage x12.27.6 160.3%   
Debt to equity ratio x0.11.0 14.2%  
Sales to assets ratio x0.80.8 103.8%   
Return on assets %5.711.4 50.1%  
Return on equity %8.324.7 33.5%  
Return on capital %10.519.1 54.8%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Exports (fob) Rs m15,617NA-   
Imports (cif) Rs m4,571NA-   
Fx inflow Rs m15,61756,152 27.8%   
Fx outflow Rs m5,8288,084 72.1%   
Net fx Rs m9,79048,068 20.4%   
CASH FLOW
From Operations Rs m2,7646,574 42.0%  
From Investments Rs m-1,432-7,124 20.1%  
From Financial Activity Rs m-1,5915,432 -29.3%  
Net Cashflow Rs m-2591,992 -13.0%  

Share Holding

Indian Promoters % 45.9 48.3 95.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 6.9 165.2%  
FIIs % 25.3 34.4 73.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.5 165.7%  
Shareholders   36,892 56,727 65.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 23, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS